PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: inGenious Targeting Laboratory, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

inGenious Targeting Laboratory Launches FLP Embryonic Stem Cell Line for Fast Mouse Model Generation - inGenious Targeting Laboratory (iTL), a leading provider of genetically modified mouse models, announced today the availability of a new embryonic stem “ES” cell line - GeneTargeting.com
inGenious Targeting Laboratory Launches FLP Embryonic Stem Cell Line for Fast Mouse Model Generation

 

NewswireToday - /newswire/ - Ronkonkoma, NY, United States, 2014/04/07 - inGenious Targeting Laboratory (iTL), a leading provider of genetically modified mouse models, announced today the availability of a new embryonic stem “ES” cell line - GeneTargeting.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

When used in the creation of genetically modified mice, these proprietary ES cells have a significant impact in reducing both the timeline and cost of generating mouse models.

Company officials describe the new FLP ES cell line as one in which the FLP transgene is silent in the ES cells but is expressed in the resulting mice. This allows iTL to produce Neo negative mice in the first generation while maintaining the integrity of the ES cells. Hence, FLP matings are no longer needed and germline transmission remains robust. This saves iTL clients 3 months in the mouse production process, allowing researchers to begin their studies faster using these genetically modified mice.

Over the last couple of years, the field of model generation has seen an unprecedented increase in its ability to produce genetically modified mice. Researchers are now looking for more sophisticated models utilizing advanced gene targeting approaches. In an effort to obtain these models, academic institutions and the biopharma industry are seeking out companies as a source of breakthrough technologies to produce these models.

“There are immediate benefits to this new cell line,” Paul Sheiffele, President of iTL, points out. “Our business model aligns us with the implementation of new technologies. Saving significant time and money on the generation of mouse models is essential in today’s funding environment. By using a synergistic combination of technologies with proven success, iTL continues to set the tone as an innovator in model generation.”

About inGenious Targeting Laboratory (iTL)

Established in 1998, inGenious Targeting Laboratory (genetargeting.com) exclusively creates mice whose genetic make-up is tailored to the client’s research needs. Clients retain all intellectual property rights to their projects. A full range of project capabilities are available including; conventional and conditional knockouts, knockin models (humanized, inducible, reporter gene/cassette insertion, point mutations), as well as novel approaches for customized mouse models. Projects are initiated immediately upon completion of design parameters and progress to completion on-site in the USA, under the supervision of a dedicated scientific Project Manager. iTL is located in Ronkonkoma, New York.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: inGenious Targeting Laboratory, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


inGenious Targeting Laboratory Launches FLP Embryonic Stem Cell Line for Fast Mouse Model Generation

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Tegan Ryan - GeneTargeting.com 
631-681-5653 tryan[.]genetargeting.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any inGenious Targeting Laboratory, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From inGenious Targeting Laboratory, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)